BUSINESS● LOW3h ago · Oct 5, 2026, 6:17 AM

CSL strikes $1.55B lixudebart deal with Alentis for rare kidney and liver diseases

Seeking Alpha Tech · global

CSL has finalized a $1.55 billion deal with Alentis for the development of lixudebart, a treatment for rare kidney and liver diseases. This significant transaction impacts the pharmaceutical and biotechnology industries.

Read at Seeking Alpha Tech Ask the Analyst about this

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

See it on the live mapEvents around the world right now

More in Business

BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSEC BUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSEC BUSINESS32m agoEuro hits 17-month low as French debt fears mount and Spain heads for snap electionEuroNews [en]BUSINESS33m agoFirmus Technologies to reserve half of $5.5B IPO for existing backers, AFR reportsSeeking Alpha Tech